Cancer drug hope for women

A NEW breast cancer drug enables women to remain disease-free for longer than the current “gold standard” treatment, researchers claimed yesterday.

The British-led ATAC trial is the largest breast cancer treatment study conducted and its latest results were presented yesterday at a symposium in San Antonio, Texas, USA.

The data demonstrated that, after nearly four years of treatment, women given anastrozole, which is marketed as Arimidex, were free of disease for longer than those taking tamoxifen.